|
Matrix
|
Parameter reduction
|
Day
|
Placebo (n)
|
GC (n)
|
UC-II (n)
|
|---|
|
Serum
|
COMP (ng/mL)
|
180
|
−51.2 ± 31.3 (53)
|
−56.5 ± 36.0 (56)
|
−69.6 ± 40.8 (53)
|
|
CRP (mg/L)
|
180
|
15.1 ± 6.33 (26)
|
9.09 ± 5.36 (28)
|
13.0 ± 4.64 (28)
|
|
Synovial
|
IL-6 (ng/mL)
|
180
|
−9.54 ± 4.83 (23)
|
−9.72 ± 5.28 (24)
|
−11.8 ± 5.37 (21)
|
|
MMP-3 (μg/mL)
|
180
|
−2.24 ± 1.26 (25)
|
−0.93 ± 0.79 (27)
|
−2.67 ± 1.85 (23)
|
- Values presented as Mean ± SE. Statistical analysis was performed on log transformed and baseline adjusted values. No significant differences were observed between the study groups (p > 0.05)
